Canada receives report of blood clot linked to AstraZeneca

A Quebec woman has developed a blood clot after receiving a COVID-19 vaccine, in Canada's first case of the rare condition.

Federal and provincial health officials say the woman got an Oxford-AstraZeneca vaccine that was produced at the Serum Institute of India, known as Covishield.

The agency says the person is now recovering at home.

Health Canada says the side-effect is extremely rare and the vaccine's benefits still outweigh its risks.

More than 700,000 doses of the vaccine have been administered in Canada.

In the House of Commons today, Health Minister Patty Hajdu was asked by the Conservatives whether her department will be conducting a review of the case.

Hajdu said there would be a review, but also accused the Conservative opposition of fear mongering.